Response to "Aspirin for Primary Prevention in Metabolic Dysfunction-Associated Steatotic Liver Disease"

Scritto il 22/01/2026
da Tsubasa Tsutsumi

No abstract

Hepatol Res. 2026 Jan 22. doi: 10.1111/hepr.70123. Online ahead of print.

NO ABSTRACT

PMID:41568574 | DOI:10.1111/hepr.70123